A. Erythroblastosis foetalis is a condition observed having fetus with Rh$^{-ve}$ blood and mother with Rh$^{+ve}$ blood.
B. Rh antigen is observed on RBCs in the majority of human beings.
C. Before blood transfusion, Rh group should also be matched.
D. Rh incompatibility is observed when a pregnant mother is Rh$^{-ve}$ and the fetus is Rh$^{+ve}$.
E. Erythroblastosis foetalis can be avoided by administering anti-Rh antibodies to the mother immediately after the delivery of the second child.
Choose the answer from the options given below :
This analysis identifies incorrect statements regarding Rh grouping, focusing on Erythroblastosis foetalis and blood transfusion compatibility.
Statement A: Erythroblastosis foetalis is a condition observed having fetus with Rh$^{-ve}$ blood and mother with Rh$^{+ve}$ blood.
Reasoning: This is incorrect. The condition, Hemolytic Disease of the Newborn/Fetus, specifically occurs when an Rh$^{-ve}$ mother carries an Rh$^{+ve}$ fetus. Maternal Rh$^{+ve}$ blood and fetal Rh$^{-ve}$ blood do not cause this condition.
Statement B: Rh antigen is observed on RBCs in the majority of human beings.
Reasoning: This is correct. Approximately 85% of the human population is Rh$^{+ve}$, meaning they possess the Rh antigen on their red blood cells.
Statement C: Before blood transfusion, Rh group should also be matched.
Reasoning: This is correct. Rh factor compatibility is crucial during blood transfusions to prevent immune responses and potential transfusion reactions, especially for individuals who may become sensitized.
Statement D: Rh incompatibility is observed when a pregnant mother is Rh$^{-ve}$ and the fetus is Rh$^{+ve}$.
Reasoning: This is correct. This specific scenario defines Rh incompatibility during pregnancy, which can lead to complications like Erythroblastosis foetalis.
Statement E: Erythroblastosis foetalis can be avoided by administering anti-Rh antibodies to the mother immediately after the delivery of the second child.
Reasoning: This is incorrect. Effective prevention involves administering anti-Rh antibodies (e.g., RhoGAM) to Rh$^{-ve}$ mothers during pregnancy (around 28 weeks) and within 72 hours after delivering an Rh$^{+ve}$ baby. This prevents the mother from developing her own antibodies (sensitization). The statement's timing ("after the second child") is inaccurate and incomplete for preventing initial sensitization.
The analysis confirms that statements A and E are factually incorrect regarding Rh grouping principles and clinical applications.